Safety and efficacy of paliperidone palmitate 1-month formulation in Chinese patients with schizophrenia: a 25-week, open-label, multicenter, Phase IV study

RATIONALE: Long-acting injectable (LAI) paliperidone palmitate 1-month formulation (PP1M) has demonstrated acceptable tolerability and favorable clinical outcomes in Western and Asian patients with schizophrenia. Hence, analysis of the outcomes of long-term PP1M treatment specifically in Chinese pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Jingping, Li, Lehua, Shi, Jianguo, Li, Yi, Xu, Xiufeng, Li, Keqing, Zhang, Lili, Cai, Shangli, Feng, Yu, Zhuo, Jianmin, Liu, Weihong, Lu, Huafei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5546821/
https://www.ncbi.nlm.nih.gov/pubmed/28814873
http://dx.doi.org/10.2147/NDT.S131224

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5546821/
https://www.ncbi.nlm.nih.gov/pubmed/28814873
http://dx.doi.org/10.2147/NDT.S131224

Ejemplares similares